Skip to main content

Zyus Life Sciences Corporation(ZYUS-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.550
Day High0.590
Open:0.590
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Zyus Life Sciences Corporation

Select a category then submit the form to load news
Newswire.ca
ZYUS Life Sciences Announces Closing of Debt Financing
Newswire.ca
ZYUS Life Sciences Announces Cancellation of LIFE Offering and Launch of Private Placement
Newswire.ca
ZYUS Life Sciences Announces Filing of Amended and Restated LIFE Offering Document
Newswire.ca
ZYUS Life Sciences Announces Amendment to Subleases and Promissory Note Agreement
GlobeNewswire
ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units
Newswire.ca
ZYUS Life Sciences Reports Preliminary Results from Ongoing Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug
Newswire.ca
ZYUS Life Sciences Corporation Announces Closing of Additional Secured Loan
Newswire.ca
ZYUS Life Sciences Announces Activation of Two Additional Clinical Sites in Phase 2a UTOPIA-1 Cancer Pain Trial
Newswire.ca
ZYUS Life Sciences Activates First Clinical Site and Enrolls First Patient in Phase 2a UTOPIA-1 Cancer Pain Trial
PR Newswire
ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering
Newswire.ca
ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering
Business Wire
ZYUS Life Sciences Strengthens Clinical Leadership with Appointment of Chief Medical Officer to Support Phase 2 Oncology Pain Trial
Business Wire
Brent H. Zettl Provides Update on Holdings of ZYUS Life Sciences Corporation
Business Wire
ZYUS Life Sciences Announces Closing of Unit Offering
Business Wire
 ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering
Business Wire
ZYUS Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain Drug
Business Wire
ZYUS Life Sciences Announces Closing of Unit Offering
Business Wire
ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering
Business Wire
ZYUS Life Sciences Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent covering Trichomylin® Formulation and Announces Unit Offering
Business Wire
ZYUS Life Sciences Corporation Announces Issuance of Bonus Warrants Pursuant to Loan Agreements
Business Wire
ZYUS Life Sciences Corporation Announces Assumption and Amendment of Promissory Note
Business Wire
ZYUS Life Sciences Corporation Announces Close of Unsecured Loan and Amendment to Prior Unsecured Loans
Business Wire
ZYUS Life Sciences Corporation Announces Closing of Unsecured Loan and Amendment of Existing Shareholder Promissory Note
Business Wire
ZYUS Life Sciences Corporation Announces Unsecured Loan
Newswire.ca
ZYUS Life Sciences Corp. Closes the Market

Profile

ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.